Umbilical cord blood stem cells
Efficacy data for use of stem cells from umbilical cord blood will be discussed by FDA's Biological Response Modifiers Advisory Committee Feb. 27. Committee will also hear updates on research programs in the Division of Monoclonal Antibodies. Meeting begins at 8 a.m. at the Holiday Inn in Silver Spring, Md...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”